Last reviewed · How we verify

NCT03329313: NADIRA

Effects of Variation of Sodium Dialysate in ICU

Recruiting now Phase 2 Last updated 30 September 2025
What this trial tests

Phase 2 trial testing Lowering sodium concentration dialysate in Acute Kidney Injury in 158 participants. Currently enrolling.

Timeline
19 April 2018
Primary endpoint
19 December 2026
19 December 2026

Quick facts

Lead sponsorUniversity Hospital, Montpellier
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment158
Start date19 April 2018
Primary completion19 December 2026
Estimated completion19 December 2026
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

Adults 18 to 80, any sex, with Acute Kidney Injury or Renal Replacement Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intermittent hemodialysis/diafiltration is a current renal replacement therapy (RRT) institued for ICU patients with AKI. For a better clinical tolerance, iinternational guidelines advise to use cold dialysate, increase duration session, decrease blood and dialysate flows, and increase level of sodium dialysate concentration (≥ 145mmol/l). Indeed, the use of a Na concentration dialysate \> 145 mmol/l improves intradialytic hemodynamic tolerance but it may also induce fluid overload by the transfert of sodium from the dialysate compartment to the blood. Yet, fluid overload has been strongly associated with mortality in critically ills. The investigators hypothesized that the use of a level in sodium dialysate at 140 mmol/l with slow low efficiency daily dialysis-filtration (SLEDD-f) will permit a fair intradialytic hemodynamic tolerance without the adverse effect of intradiaclytic Na loading from the dialysate. Two randomized groups of ICU AKI patients treated by SLEDD-f will be compared in terms of intradialytic hemodynamic tolerance and overload accordong to 140 or 145 mmol/l of Na in the dialysate

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Perioperative Acute Kidney Injury.
    Gumbert SD, Kork F, Jackson ML, Vanga N, et al · · 2020 · cited 209× · PMID 31687986 · DOI 10.1097/aln.0000000000002968
  2. Nanotechnology-Enhanced Extracellular Vesicles -Based Chipsets in Early Cancer Detection and Theranostics.
    Maitra S, Sarkar S, Chandra M, Ballal S, et al · · 2025 · cited 1× · PMID 40837698 · DOI 10.2147/ijn.s529128

Verify or expand the search:

Other recruiting trials for Acute Kidney Injury

Currently open trials in the same condition.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03329313.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing